Your Teeth Will Regrow: Japan's Tooth-Regeneration Drug Enters Human Trials — Dentures Retire by 2040

The Question

Humans grow two sets of teeth in a lifetime: the baby teeth that fall out in childhood and the adult teeth that replace them. That has always seemed like a hard biological limit — lose an adult tooth, and your only options are a bridge, an implant, or a denture. But biology hid a surprise. Studies of the jaw show that many people carry the faint beginnings of extra teeth, dormant buds that ordinarily stall and never emerge. The clearest proof comes from a condition called hyperdontia, in which some people simply grow additional teeth beyond the normal count — living evidence that the body retains the instructions to build more.

If the blueprint for a third set of teeth already exists inside us, a natural question follows: could it be switched back on? For most of medical history the idea would have sounded like fantasy. What has changed is that scientists have identified a specific molecular brake that keeps those extra teeth from forming — and have built a drug to release it. The question is no longer whether spare teeth exist in principle, but whether a medicine can coax them into the mouth safely.

What the Evidence Shows

The work centres on a Japanese team led by Katsu Takahashi, a dental researcher at Kitano Hospital in Osaka, working with the company Toregem Biopharma. His group focused on a protein called USAG-1, which acts as a brake on tooth growth — it suppresses the signals that would otherwise tell buds to develop. Reasoning that removing the brake might release dormant teeth, the researchers created an antibody drug that blocks USAG-1. In animals, the results were striking: mice and ferrets born missing teeth grew new ones after treatment, and the regrown teeth appeared normal in shape and position.

The decisive step came in 2024, when the team began human clinical trials at Kyoto University Hospital. The first phase, as is standard for a new medicine, focuses on safety in healthy adults. The initial therapeutic target is not the general public but people born with congenital tooth agenesis — a condition in which individuals are missing several or many teeth from birth, often causing serious difficulty eating and speaking. If the drug proves safe and effective there, the researchers hope to broaden it toward the far larger group of people who have lost teeth to decay, gum disease, or injury.

The context makes this genuinely significant. For all its polish, the way modern dentistry replaces a lost tooth has not changed in concept for a very long time: it substitutes an artificial object — a denture that sits on the gums or an implant screwed into the bone — for the real thing. Billions of people worldwide have lost teeth, and tooth loss rises sharply with age. A treatment that regrows a patient's own living tooth, rather than fitting a manufactured replacement, would be a categorical shift, not merely a better version of what already exists.

Why This Is Happening

The biological target is unusually well understood. Rather than trying to build a tooth from scratch, the approach works with a mechanism the body already possesses — dormant buds and a known protein brake holding them back. Removing a single brake is a far simpler and more plausible intervention than growing an organ artificially, which is why this line of research has advanced from animals to humans faster than most regenerative medicine.

The unmet need is vast and growing. Tooth loss affects an enormous share of humanity and worsens with an ageing global population. Dentures and implants, though effective, are costly, imperfect, and sometimes poorly tolerated. That immense demand gives researchers, investors, and regulators strong reasons to pursue and support a regenerative alternative that could serve people whom current options fail.

Japan's clinical and regulatory environment favours the attempt. The country has deep expertise in regenerative medicine and a research culture willing to pursue long-horizon dental science. Starting with a defined patient group — children and adults born missing teeth — gives the trials a clear, ethically compelling focus and a realistic path through approval before any broader use is considered.

What Could Happen

What Can We Do

A working tooth-regeneration drug is still years away, and the sensible response is patience paired with attention rather than premature hope.

Keep protecting the teeth you have. Even in the best case, regeneration will arrive gradually and be reserved at first for specific patients. Brushing, flossing, and regular dental care remain by far the most reliable way to keep your natural teeth. No pipeline drug is a reason to neglect the basics that already work.

Follow the trials, not the headlines. This field attracts breathless coverage that outruns the evidence. Watch for peer-reviewed results and official regulatory milestones from the Japanese trials, which give an honest read on progress. Treat any claim of imminent, universal tooth regrowth with healthy scepticism until the data support it.

Support patients born without teeth. The first and clearest beneficiaries are people with congenital tooth agenesis, who often face lifelong difficulty and cost. Backing research and coverage aimed at this group is both the most ethical priority and the route through which the broader therapy is most likely to arrive.

Weigh today's options on today's evidence. If you need a tooth replaced now, decide based on proven implants and dentures, not on a treatment still in trials. Regeneration may transform dentistry within a couple of decades, but present decisions should rest on what is available and reliable today.